A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.

ABSTRACT:

Background

Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after transplantation. We wanted to prospectively assess feasibility of systemic antitumor treatment with sorafenib as neoadjuvant treatment for hepatocellular carcinoma while waiting for liver transplantation, evaluating tolerability, toxicity and posttransplant morbidity. We also wanted to evaluate perfusion CT parameters to assess tumor properties and response early after start of sorafenib treatment in patients with early hepatocellular carcinoma.

Methods

Twelve patients assigned for liver transplantation due to hepatocellular carcinoma, w

SUBMITTER: Eilard MS 

PROVIDER: S-EPMC6560824 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature